Comment
Author: Admin | 2025-04-28
2019-06-06 Itraconazole dry powders ES2916413T3 (es) 2022-06-30 Una composición farmacéutica en polvo seco para inhalación que comprende una hormona tiroidea US10034857B2 (en) 2018-07-31 Triptan powders for pulmonary delivery CN102920678A (zh) 2013-02-13 一种奥氮平固体制剂及其制备方法 US20060222599A1 (en) 2006-10-05 Inhalative powder formulations containing the CGRP-antagonist 1 [N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine US20240033218A1 (en) 2024-02-01 Dihydroergotamine dry powder formulations and methods of use US20170304197A1 (en) 2017-10-26 Formulations containing tiotropium, amino acid and acid and methods thereof Legal Events Date Code Title Description 2016-07-18 AS Assignment Owner name: CIVITAS THERAPEUTICS, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LIPP, MICHAEL M.;REEL/FRAME:039179/0407 Effective date: 20160609 2019-01-08 STPP Information on status: patent application and granting procedure in general Free format text: NON FINAL ACTION MAILED 2019-07-15 STPP Information on status: patent application and granting procedure in general Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER 2019-09-10 STPP Information on status: patent application and granting procedure in general Free format text: FINAL REJECTION MAILED 2020-11-05 STCB Information on status: application discontinuation Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION
Add Comment